The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-linetreatment. Materials and MethodsWe selected patients with advanced non-small cell lung cancer (NSCLC) who received treatmentwith platinum/vinorelbine at Chungnam National University Hospital from August2001 to December 2013. The primary end point was the response rate, and secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. ResultsThirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients[0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressivedisease, 14 patients [40.0%]). A significantly higher response rate was observed forpatients who had responded to previous chemotherapy than for those who did not (34.8%[8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patientswith non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS thanpatients with poor performance status and smokers (14 months vs. 4 months, p=0.02;18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles. ConclusionPlatinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicitywas tolerable, in patients with advanced NSCLC.
Abstract
Purpose There is no regimen that is strongly recommended for more than second-line treatment. We investigated the efficacy and safety of platinum/vinorelbine as more than second-linetreatment. Materials and MethodsWe selected patients with advanced non-small cell lung cancer (NSCLC) who received treatmentwith platinum/vinorelbine at Chungnam National University Hospital from August2001 to December 2013. The primary end point was the response rate, and secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. ResultsThirty-five patients were enrolled. Response rate was 22.9% (complete response, 0 patients[0%]; partial response, eight patients [22.9%]; stable disease, 10 patients [28.6%]; progressivedisease, 14 patients [40.0%]). A significantly higher response rate was observed forpatients who had responded to previous chemotherapy than for those who did not (34.8%[8/23] vs. 0% [0/12], p=0.020). The median PFS was 4 months (range, 1 to 21 months). Patients with adenocarcinoma and non-smokers had a significantly longer PFS than patientswith non-adenocarcinoma and smokers (5 months vs. 2 months, p=0.007; 4.5 months vs. 2 months, p=0.046, respectively). The median OS was 10 months (range, 1 to 41 months). Patients with good performance status and non-smokers had a significantly longer OS thanpatients with poor performance status and smokers (14 months vs. 4 months, p=0.02;18.5 months vs. 6 months, p=0.049, respectively). The main serious adverse event (grade3 or 4) was neutropenia (15 events, 13.3%) in a total of 113 cycles. ConclusionPlatinum/vinorelbine was effective as more than second-line chemotherapy, and the toxicitywas tolerable, in patients with advanced NSCLC.
참고문헌 (16)
- Asahina H, "Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer", Clin Lung Cancer, 13, pp.39~43 (2012)
- Girard N, "Third-line chemotherapy in advanced non-small cell lung cancer : identifying the candidates for routine practice", J Thorac Oncol, 4, pp.1544~1549 (2009)
- "NCCN clinical practice guidelines in oncology. Non-small cell lung cancer version 3.2014"[URL]
- Shepherd FA, "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy", J Clin Oncol, 18, pp.2095~2103 (2000)
- Shepherd FA, "Erlotinib in previously treated non-small-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
- Hanna N, "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy", J Clin Oncol, 22, pp.1589~1597 (2004)
- Thatcher N, "Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall-cell lung cancer : results from a randomised, placebocontrolled, multicentre study(Iressa Survival Evaluation in Lung Cancer)", Lancet, 366, pp.1527~1537 (2005)
- Ohe Y, "Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced nonsmall-cell lung cancer : Four-Arm Cooperative Study in Japan", Ann Oncol, 18, pp.317~323 (2007)
- Fossella F, "Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer : the TAX 326 study group", J Clin Oncol, 21, pp.3016~3024 (2003)
- Park SJ, "Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer", Oncol Lett, 1, pp.51~55 (2010)
- Murillo JR Jr, "Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer", Oncologist, 11, pp.1095~1099 (2006)
- Chang MH, "The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer", Lung Cancer, 69, pp.323~329 (2010)
- Sun JM, "Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer", Jpn J Clin Oncol, 39, pp.27~32 (2009)
- Kanat O, "Single-agent vinorelbine as third-line chemotherapy for refractory non-small cell lung cancer", Turk J Cancer, 36, pp.133~137 (2006)
- Azzoli CG, "2011 Focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer", J Clin Oncol, 29, pp.3825~3831 (2011)
- Vinolas N, "Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-smallcell lung cancer patients treated with cisplatin plus vinorelbine", Lung Cancer, 71, pp.191~198 (2011)